Published in Hered Cancer Clin Pract on July 15, 2004
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst (1997) 3.92
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med (1995) 2.83
Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ (1995) 2.80
Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst (1997) 2.74
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst (1997) 2.57
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet (2002) 2.57
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A (1997) 2.54
Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res (1997) 2.18
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol (1995) 2.04
Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet (2001) 2.03
A systematic review and meta-analysis of familial prostate cancer risk. BJU Int (2003) 2.01
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol (1998) 1.94
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet (2002) 1.86
The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res (1995) 1.84
An investigation of the familial aspects of carcinoma of the prostate. Cancer (1960) 1.75
Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet (2000) 1.69
Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet (1997) 1.68
Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet (2000) 1.64
Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet (1998) 1.63
BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res (2004) 1.61
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
Where are the prostate cancer genes?--A summary of eight genome wide searches. Prostate (2003) 1.60
Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet (2000) 1.58
Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet (2000) 1.57
A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet (2000) 1.51
BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med (Berl) (1997) 1.49
Familial patterns of prostate cancer: a case-control analysis. J Urol (1991) 1.45
Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer (2003) 1.44
Sexual factors in the epidemiology of cancer of the prostate. J Chronic Dis (1971) 1.44
Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer (1995) 1.43
Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate (2003) 1.42
Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res (2000) 1.38
Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet (1999) 1.37
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Epidemiology of prostatic cancer: a case-control study. Prostate (1990) 1.31
Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer (1996) 1.30
NBS1 is a prostate cancer susceptibility gene. Cancer Res (2004) 1.24
Re: prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst (1997) 1.23
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab (1996) 1.22
Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate (2003) 1.22
Heredity and prostate cancer: a study of World War II veteran twins. Prostate (1997) 1.22
Some epidemiologic variables in prostatic carcinoma in California. Prev Med (1974) 1.21
Genetic predisposition, environment and cancer incidence: a nationwide twin study in Finland, 1976-1995. Int J Cancer (1999) 1.20
Update on chemoprevention of prostate cancer. Curr Opin Urol (2004) 1.18
Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst (1995) 1.15
Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate (2003) 1.15
Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res (1997) 1.14
Genomic scan of 254 hereditary prostate cancer families. Prostate (2003) 1.14
A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet (2003) 1.13
Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis (1999) 1.12
Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol (1997) 1.11
Neoplastic diseases in families of breast cancer patients. J Med Genet (1994) 1.11
Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. Prostate (2003) 1.11
In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet (1999) 1.10
Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet (2003) 1.10
Family history and prostate cancer risk. Am J Epidemiol (1996) 1.07
Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet (2000) 1.04
Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. Prostate (2003) 1.04
Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate (2003) 1.01
Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology (1998) 1.00
Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol (1997) 0.99
Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate (1985) 0.98
Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer (1999) 0.98
Epidemiologic study of prostatic cancer: preliminary report. Cancer Treat Rep (1977) 0.96
Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum Mol Genet (1999) 0.96
[Clinico-statistical and genetic research on neoplasms of the prostate]. Acta Genet Stat Med (1957) 0.96
Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics (2001) 0.95
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer (1999) 0.94
Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer (1997) 0.93
Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet (2001) 0.93
No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet (2003) 0.93
Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet (2001) 0.93
Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev (2002) 0.91
A screening study of prostate cancer in high risk families. J Urol (1992) 0.90
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Cancer (2002) 0.89
Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg. Prostate (1991) 0.89
Familial breast cancer risks. Effects of prostate and other cancers. Cancer (1993) 0.89
Familial aspects of prostate cancer: a case control study. J Urol (1995) 0.88
Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer (2003) 0.88
Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer (2003) 0.87
RNASEL mutations in hereditary prostate cancer. J Med Genet (2003) 0.87
Variations in DNA elucidate molecular networks that cause disease. Nature (2008) 12.04
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Dark matter in the genome: evidence of widespread transcription detected by microarray tiling experiments. Trends Genet (2005) 4.56
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet (2005) 3.74
MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat (2014) 3.46
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res (2002) 2.09
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene (2004) 1.90
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat Genet (2013) 1.58
Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn (2007) 1.55
Sexual activity and prostate cancer risk in men diagnosed at a younger age. BJU Int (2008) 1.43
We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC). Psychooncology (2004) 1.38
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2009) 1.25
Integrating siRNA and protein-protein interaction data to identify an expanded insulin signaling network. Genome Res (2009) 1.17
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology (2009) 1.05
BRCA1/2 predictive testing: a study of uptake in two centres. Eur J Hum Genet (2004) 1.02
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer (2007) 1.01
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One (2010) 1.01
The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl (2012) 1.00
Family stories and the use of heuristics: women from suspected hereditary breast and ovarian cancer (HBOC) families. Sociol Health Illn (2003) 1.00
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate (2010) 0.99
Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. Eur J Hum Genet (2011) 0.99
Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. Cancer Res (2006) 0.96
Exon and junction microarrays detect widespread mouse strain- and sex-bias expression differences. BMC Genomics (2008) 0.94
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res (2006) 0.94
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat (2010) 0.93
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther (2007) 0.91
Reverse engineering adverse outcome pathways. Environ Toxicol Chem (2011) 0.90
Genetic testing for breast and ovarian cancer predisposition: cancer burden and responsibility. J Health Psychol (2002) 0.90
Dietary fat and early-onset prostate cancer risk. Br J Nutr (2010) 0.90
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab (2014) 0.90
Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood (2002) 0.89
Looking past the obvious: experiences of altered masculinity in penile cancer. Psychooncology (2010) 0.89
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res (2006) 0.86
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev (2006) 0.86
The steady state anaerobic digestion of Laminaria hyperborea--effect of hydraulic residence on biogas production and bacterial community composition. Bioresour Technol (2013) 0.85
A transcriptomics-based biological framework for studying mechanisms of endocrine disruption in small fish species. Aquat Toxicol (2010) 0.85
Outcome of early detection and radiotherapy for occult spinal cord compression. Radiother Oncol (2007) 0.84
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer (2007) 0.84
No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat (2008) 0.84
Mechanistic indicators of childhood asthma (MICA) study: piloting an integrative design for evaluating environmental health. BMC Public Health (2011) 0.83
"Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation. J Genet Couns (2006) 0.83
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk. Int J Cancer (2013) 0.82
Ownership of uncertainty: healthcare professionals counseling and treating women from hereditary breast and ovarian cancer families who receive an inconclusive BRCA1/2 genetic test result. Genet Test Mol Biomarkers (2011) 0.81
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2014) 0.81
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett (2006) 0.80
Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. Cancer Epidemiol Biomarkers Prev (2009) 0.80
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One (2012) 0.80
Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 0.79
Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. Future Oncol (2014) 0.79
Exploring men's experiences of penile cancer surgery to improve rehabilitation. Nurs Times (2009) 0.79
Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res (2011) 0.79
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep (2013) 0.78
Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal women. Breast Cancer Res Treat (2006) 0.78
Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines. Fam Cancer (2008) 0.77
Ductal approaches to assessment and management of women at high risk for developing breast cancer. Breast Cancer Res (2004) 0.76
Appreciative inquiry into lifeskills-based HIV/AIDS education in South African schools. Afr J AIDS Res (2009) 0.76
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Med Genet (2012) 0.76
An assessment of the shared allelic architecture between type II diabetes and prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.76
Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic". Hered Cancer Clin Pract (2004) 0.75
Clarifying coals. Science (2009) 0.75
Medicaid and children: a national disgrace. Health Aff (Millwood) (2003) 0.75
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Res (2016) 0.75
Male body image following acquired brain injury. Brain Inj (2005) 0.75
Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers. Fam Cancer (2014) 0.75
A case study application of the Aggregate Exposure Pathway (AEP) and Adverse Outcome Pathway (AOP) frameworks to facilitate the integration of human health and ecological endpoints for Cumulative Risk Assessment (CRA). Environ Sci Technol (2017) 0.75